Is Amgen An Undervalued Stock Or Value Trap?

Amgen (AMGN) stock is at an interesting point right now. If you bet on it, you are betting on a company that's growing reasonably, is sustaining good cash flow and margin, has a low-debt to market ...

Amgen: Time For An Upgrade? Yes, I Think So

Amgen Inc. upgraded to cautious Buy: pipeline growth drivers, margin upside, and risk/reward near lows. Click for this AMGN ...
KXAN

AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
Health Affairs

Amgen’s Retreat: Denmark, Repatha, And The Collision Course Of US MFN Pricing Policy

Repatha is not a drug where Amgen has pricing power to absorb such exposure. The Denmark exit should be read as a rational, if disruptive, response to that specific vulnerability — not as the ...
Nasdaq

Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season

Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The company has been recording consistently strong top-line performance. Amgen ...